Artículo Original lesions. Rev Med Chile 2014; 142: 1181-92. 15.- Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993; 71: 745-50. 16.- Guías clínicas AUGE: Cáncer Gástrico Marzo 2014. Disponible en: http://web. minsal.cl/sites/default/files/files/GPC% 20G%C3%A1strico%20(PL).pdf MINSAL Consultado el 10 de octubre de 2016. 17.- Latorre G, Álvarez J, Ivanovic-Zuvic D, Valdivia G, Margozzini P, Chianale J, et al. Cobertura de la estrategia preventiva de cáncer gástrico en Chile: resultados de la Encuesta Nacional de Salud 2009-2010. Rev Med Chile 2015; 143: 1198-205. 18.- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81. 19.- Den Hoed CM1, Holster IL, Capelle LG, de Vries AC, den Hartog B, Ter Borg F, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy 2013; 45: 249-56. 20.- Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW. The long 214 Protocolo Sydne y y lesi ones p remalignas g ást ricas - G. Latorre S. et al. term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50: 378-81. 21.- Gómez M, Ricaurte O, Gutiérrez O. Costo efectividad de la endoscopia digestiva alta como prueba diagnóstica en una campaña para detección del cáncer gástrico. Rev Colomb Gastroent 2009; 24: 34-50. 22.- Kim GH, Liang PS, Bang SJ, Hwang JH. Screening and surveillance for gastric cancer in the United States: Is it needed? Gastrointest Endosc 2016; 84: 18-28. 23.- González CA, Sanz-Anquela JM, Gisbert JP, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer 2013; 133: 1023-32. 24.- Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74-94. 25.- Guarner J, Herrera-Goepfert R, Mohar A, Smith C, Schofield A, Halperin D, et al. Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. Hum Pathol 2003; 34: 28-31. 26.- Rollán A. Sistema OLGA: “Operative Link for Gastritis Assessment.” Gastroenterología latinoamericana 2012; 23: 107-9. 27.- Rugge M, Cassaro M, Pennelli G, Leandro G, Di Mario F, Farinati F. Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut 2003; 52: 1387-8. 28.- Ricuarte O, Gutiérrez O, Cardona H, Kim JG, Graham DY, El-Zimaity HMT. Atrophic gastritis in young children and adolescents. J Clin Pathol 2005; 58: 1189-93. 29.- Satoh K, Kimura K, Taniguchi Y, Kihira K, Takimoto T, Saifuku K, et al. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 1998; 93: 569-73. 30.- Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. Journal of cancer prevention 2015; 20: 25-40. 31.- Wolf E-M, Plieschnegger W, Geppert M, et al. Changing prevalence patterns in endoscopic and histological diagnosis of gastritis? Data from a cross-sectional Central European multicentre study. Dig Liver Dis 2014; 46: 412-8. Gastroenterol. latinoam 2016; Vol 27, Nº 4: 207-214
gastro 4
To see the actual publication please follow the link above